Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma
Authors: Maria E. Cabanillas, Ramona Dadu, Renata Ferrarotto, Maria Gule-Monroe, Suyu Liu, Bryan Fellman, Michelle D. Williams, Mark Zafereo, Jennifer R. Wang, Charles Lu, Matthew Ning, Brian A. McKinley, Scott E. Woodman, Dzifa Duose, Gary B. Gunn, Naifa L. Busaidy, Ahmed N Alrawi, Claudio A Arrechedera, Kimberly S Ayers, Caludia A Bedoya, Elizabeth Burton, Connie A Chon, Randy A Chu, Shadarra D Crosby, Jonathan Do, Cibelle FP Lima, Fu Szu-Chin, Andy Futreal, Ana L Garcia, Celia Garica-Prieto, Swati Gite, Curtis Gumbs, Kristin J Hargraves, Meng He, Chacha Horombe, Heladio P Ibarguen, Stacy Jackson, Jeena J Jacob, Mei Jiang, Isha Khanduri, Walter K Kinyua, Mark Knafl, Wenhua Lang, Latasha D Little, Wei Lu, Saradhi Mallampati, Mary GT Mendoza, Funda Meric-Bernstam, Mohammad M Mohammad, Mario LM Piubelli, Sabitha Prabhakaran, Kenna R Shaw, Xiaofei Song, Sandesh Subramanya, Baohua Sun, Shumaila Virani, Wanlin Wang, Ignacio Wistuba, Scott E Woodman, Mingchu Xu, Jianhua Zhang, Qingxiu C Zhang, Shanyu Zhang
Journal: JAMA Oncology (2024)

Importance Anaplastic thyroid carcinoma (ATC) is a rare and lethal cancer. Although progress has been made in recent years in patients with mutated BRAF tumors, those who respond initially eventually die of their disease; furthermore, there are no approved therapies for non-BRAF mutated tumors. Objective To determine whether treatment with matched-targeted therapy plus immune checkpoint inhibitors were associated with improved overall survival (OS). Design, Setting, and Participants A phase 2 trial at a single center, tertiary institution with parallel cohorts, assigning treatment with targeted therapy according to the tumor mutation status. Patients with mutated BRAF V600E tumors received vemurafenib/cobimetinib plus atezolizumab (cohort 1); those with mutated RAS (NRAS, KRAS, or HRAS) or NF1/2 tumors received cobimetinib plus atezolizumab (cohort 2). Patients without any of these variants were assigned to receive bevacizumab plus atezolizumab (cohort 3). Patients were enrolled from August 3, 2017, to July 7, 2021. All consecutive, systemic therapy-naive patients with ATC with active disease and who met eligibility criteria were considered for participation. The analysis was conducted in September 2023. Interventions Patients were assigned to targeted therapy based on the driver mutation as follow: BRAF V600E (cohort 1, vemurafenib plus cobimetinib), RAS/NF (cohort 2, cobimetinib), or non- BRAF / RAS / NF (cohort 3, bevacizumab). All received atezolizumab. Main Outcomes and Measures The primary outcome of the study was median OS of the entire targeted therapy cohort, compared with historical median OS of 5 months. Results Forty-three patients with ATC were enrolled in the targeted therapy cohorts, of which 42 were included in the primary analysis. The median OS in patients across these 3 cohorts was 19 months (95% CI, 7.79-43.24). Median OS and progression-free survival per cohort were as follows: cohort 1: 43 months (95% CI, 16-not estimable [NE]), 13.9 months (6.6-64.1); cohort 2: 8.7 months (95% CI, 5.1-37.0) and 4.8 months (1.8-14.7); cohort 3 (vascular endothelial growth factor inhibitor group): 6.21 months (4.1-NE) and 1.3 months (1.3-NE), respectively. Conclusions and Relevance In this nonrandomized clinical trial, atezolizumab combined with targeted therapy resulted in a longer median OS than historical landmark, achieving the study’s primary end point, with cohort 1 achieving the longest OS. Trial Registration ClinicalTrials.gov Identifier: NCT03181100